Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
Am J Gastroenterol ; 119(5): 982-986, 2024 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-38240303

RESUMO

INTRODUCTION: Management of hepatic encephalopathy relies on self-titration of lactulose. In this feasibility trial, we assess an artificial intelligence-enabled tool to guide lactulose use through a smartphone application. METHODS: Subjects with hepatic encephalopathy on lactulose captured bowel movement pictures during lead-in and intervention phases. During the intervention phase, daily feedback on lactulose titration was delivered through the application. Goals were determined according to number of bowel movement and Bristol Stool Scale reports. RESULTS: Subjects completed the study with more than 80% satisfaction. In the lead-in phase, less compliant subjects achieved Bristol Stool Scale goal on 62/111 (56%) of days compared with 107/136 (79%) in the intervention phase ( P = 0.041), while the most compliant subjects showed no difference. Severe/recurrent hepatic encephalopathy group achieved Bristol Stool Scale goal on 80/104 (77%) days in the lead-in phase and 90/110 (82%) days in the intervention phase ( P = NS), compared with 89/143 (62%) days and 86/127 (68%) days in the stable group. DISCUSSION: Dieta application is a promising tool for objective Bowel Movement/Bristol Stool Scale tracking for hepatic encephalopathy and may potentially be used to assist with lactulose titration.


Assuntos
Inteligência Artificial , Estudos de Viabilidade , Fezes , Fármacos Gastrointestinais , Encefalopatia Hepática , Lactulose , Aplicativos Móveis , Smartphone , Humanos , Encefalopatia Hepática/tratamento farmacológico , Lactulose/administração & dosagem , Masculino , Feminino , Pessoa de Meia-Idade , Fezes/química , Idoso , Fármacos Gastrointestinais/administração & dosagem , Fármacos Gastrointestinais/uso terapêutico
2.
An. bras. dermatol ; 96(1): 85-87, Jan.-Feb. 2021. graf
Artigo em Inglês | LILACS | ID: biblio-1152795

RESUMO

Abstract There have been several clinical manifestations associated with SARS-CoV-2 infection since 2019, including dermatological signs and symptoms. In this article, the authors report a case of a previously healthy patient with COVID-19 who was mistakenly diagnosed with dengue fever due to a skin rash. By the time the patient's investigation was initiated, Joinville (Santa Catarina, Brazil) had approximately 5,000 confirmed cases of dengue fever and 1,700 cases of COVID-19 in 2020. Thus, the authors emphasize that in endemic regions such as Brazil, the two diseases must be considered until proven otherwise. Finally, the authors warn of the possibility of co-infection with these two viruses in regions that are facing both epidemics at the same time.


Assuntos
Humanos , Dengue/diagnóstico , Exantema/diagnóstico , COVID-19 , Brasil , SARS-CoV-2
3.
An Bras Dermatol ; 96(1): 85-87, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33281008

RESUMO

There have been several clinical manifestations associated with SARS-CoV-2 infection since 2019, including dermatological signs and symptoms. In this article, the authors report a case of a previously healthy patient with COVID-19 who was mistakenly diagnosed with dengue fever due to a skin rash. By the time the patient's investigation was initiated, Joinville (Santa Catarina, Brazil) had approximately 5,000 confirmed cases of dengue fever and 1,700 cases of COVID-19 in 2020. Thus, the authors emphasize that in endemic regions such as Brazil, the two diseases must be considered until proven otherwise. Finally, the authors warn of the possibility of co-infection with these two viruses in regions that are facing both epidemics at the same time.


Assuntos
COVID-19 , Dengue , Exantema , Brasil , Dengue/diagnóstico , Exantema/diagnóstico , Humanos , SARS-CoV-2
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA